Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

L-165041

Catalog No: tcsc0826

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
79558-09-1

Formula:
$C_{22}H_{26}O_7$

Pathway:
Cell Cycle/DNA Damage

Target:
PPAR

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
402.44

Product Description

L-165041 is a cell permeable **PPARδ** agonist, with **K_i**s of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

adipocyte differentiation in NIH-PPARδ cells.

IC50 & Target: Ki: 6 nM (PPARδ), appr 730 nM (PPARγ)[1]

In Vitro: L-165041 is a PPARδ agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively[1]. L-165041 (1 or 5 μM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 μM)inhibits PPARδ-independent, VEGF-induced angiogenesis[2]. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF[4].

In Vivo: L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group[3].